Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.
Company Details
- Employees
- 6
- Founded
- -
- Address
- The Precinct, Level 2, 315 Brunswick St,australia
- en****@****ech.com
- Industry
- Biotechnology
- Website
- kirabiotech.com
- HQ
- Fortitude Valley, QLD
Kira Biotech Pty Ltd Questions
Kira Biotech Pty Ltd's website is kirabiotech.com
Kira Biotech Pty Ltd's LinkedIn profile is https://au.linkedin.com/company/kira-biotech-pty-ltd
Kira Biotech Pty Ltd has
6 employees.
View email and phone details for 6
employees at Kira Biotech Pty Ltd.
Kira Biotech Pty Ltd's industry is
Biotechnology
Kira Biotech Pty Ltd's top competitors are
Inosi Therapeutics Pty Ltd,
Dimerix Limited,
Audax Biosciences,
Prescient Therapeutics,
Kinoxis Therapeutics Pty Ltd,
Gertrude Biomedical,
Imugene Limited,
Argenica Therapeutics,
Carina Biotech,
Cartherics Pty Ltd.
Kira Biotech Pty Ltd's support email address is enquiries@kirabiotech.com
Kira Biotech Pty Ltd's categories are Biotechnology
Kira Biotech Pty Ltd's founding year is 2019
